PT  - JOURNAL ARTICLE
AU  - Dasaro, Christopher
AU  - Haslam, Alyson
AU  - Prasad, Vinay
TI  - Cardiovascular drugs approved for heart failure with reduced ejection fraction and/or post-myocardial infarction exert consistent effects in both populations: A meta-analysis and meta-regression of randomized controlled trials
AID  - 10.1101/2024.02.05.24301181
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.05.24301181
4099  - http://medrxiv.org/content/early/2024/02/06/2024.02.05.24301181.short
4100  - http://medrxiv.org/content/early/2024/02/06/2024.02.05.24301181.full
AB  - Background Heart failure (HF) following an acute myocardial infarction (post-MI HF) has been studied as an additional sub-type of HF to broaden the indications for HF drugs. Post-MI HF and HFrEF are pathophysiologically similar and share pharmacotherapies. In this meta-analysis, we examined the concordance between all-cause mortality data for drugs indicated for HFrEF and post-MI HF. We used our analysis to calculate the projected all-cause mortality hazard ratios (HRs) for the pending dapagliflozin (DAPA-MI) and empagliflozin (EMPACT-MI) post-MI HF trials.Methods Using CenterWatch and UpToDate, we identified all FDA-approved drugs for NYHA Class II to IV HFrEF. We searched each of these drugs on FDALabel and ClinicalTrials.gov to identify their registration trials measuring all-cause mortality for HFrEF and, if available, in the post-MI setting—including trials where participants displayed a left ventricular ejection fraction of <40% (“post-MI HF”). For each of the included studies, we extracted the all-cause mortality HRs, their 95% confidence intervals, and the control-group used. For all drugs studied in both indications, we plotted the all-cause mortality HRs for HFrEF against those for post-MI (HF) and calculated the linear regressions.Results This meta-regression pooled data from 29 completed trials underlying 20 drugs. Two pending trials were also analyzed. Nine drugs (metoprolol, carvedilol, spironolactone, eplerenone, sacubitril-valsartan, lisinopril, enalapril, valsartan, losartan) had all-cause mortality data in both HFrEF and post-MI generally, with a linear coefficient of determination of 0.93. Five of these drugs (carvedilol, eplerenone, sacubitril-valsartan, valsartan, losartan) were studied in both HFrEF and non-acute post-MI HF, displaying a linear coefficient of determination of 0.99. Using our model, we predict the all-cause mortality HRs that will be observed in the EMPACT-MI and DAPA-MI trials will be 0.85 and 0.89, respectively.Conclusions In this meta-regression of registration trials for drugs studied in both HFrEF and post-MI (HF), all-cause mortality effects were highly concordant. We also find asymmetries in the assessment of HF drug indications, whereby drugs are seldom assessed for an all-cause mortality benefit in both HFrEF and in post-MI HF. Future studies may use these results to guide future HF RCT development.Competing Interest StatementSources of Funding & Disclosures: Vinay Prasads Disclosures. (Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, Medscape, and MedPage (Honoraria) Grand Rounds/lectures from universities, medical centers, non-profits, and professional societies. (Consulting) UnitedHealthcare and OptumRX. (Other) Plenary Session podcast has Patreon backers, YouTube, and Substack. Alyson Haslam has no disclosures to report. Christopher Dasaro has no disclosures to report.Funding StatementSources of Funding & Disclosures: Vinay Prasads Disclosures. (Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, Medscape, and MedPage (Honoraria) Grand Rounds/lectures from universities, medical centers, non-profits, and professional societies. (Consulting) UnitedHealthcare and OptumRX. (Other) Plenary Session podcast has Patreon backers, YouTube, and Substack. Alyson Haslam has no disclosures to report. Christopher Dasaro has no disclosures to report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Drugs were procured from: https://www.uptodate.com/contents/primary-pharmacologic-therapy-for-heart-failure-with-reduced-ejection-fraction and https://www.centerwatch.com/directories/1067-fda-approved-drugs/topic/388-heart-failure . Referenced trials are listed in supplementary tables and/or our references in the manuscript. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors